Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.
Certain diabetes medications show potential to reduce substance use disorder risk, opening new treatment possibilities.
This PubMed record reports background: Substance use disorders continue to cause significant morbidity and mortality. The study was classified as randomized controlled trial and is relevant to treatment innovation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of dual diagnosis
Why it surfaced
Conservative triage based on the PubMed abstract, randomized controlled trial, clinical relevance, and unmet-need signals.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.